Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) saw a significant decline in short interest in the month of October. As of October 31st, there was short interest totalling 1,790,000 shares, a decline of 19.0% from the October 15th total of 2,210,000 shares. Based on an average daily volume of 458,300 shares, the short-interest ratio is presently 3.9 days. Currently, 2.1% of the company's shares are short sold.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on CMPX shares. Leerink Partners cut shares of Compass Therapeutics from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $5.00 to $4.00 in a report on Friday. Wedbush reaffirmed an "outperform" rating and issued a $8.00 target price on shares of Compass Therapeutics in a research report on Wednesday, August 7th. HC Wainwright reiterated a "buy" rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Monday, November 11th. LADENBURG THALM/SH SH upgraded Compass Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 price objective for the company in a report on Monday, September 16th. Finally, Leerink Partnrs cut Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, Compass Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $6.75.

Compass Therapeutics Stock Down 13.2 %

CMPX stock traded down $0.21 during midday trading on Friday, hitting $1.38. The company's stock had a trading volume of 1,348,934 shares, compared to its average volume of 455,768. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.34. The stock's 50-day moving average price is $1.75 and its 200 day moving average price is $1.42.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.03. Analysts expect that Compass Therapeutics will post -0.37 EPS for the current year.

Institutional Trading of Compass Therapeutics

Hedge funds have recently made changes to their positions in the company. Bleakley Financial Group LLC bought a new stake in Compass Therapeutics in the 1st quarter valued at about $80,000. Renaissance Technologies LLC lifted its stake in shares of Compass Therapeutics by 99.7% during the 2nd quarter. Renaissance Technologies LLC now owns 140,600 shares of the company's stock valued at $141,000 after buying an additional 70,200 shares in the last quarter. Rhumbline Advisers boosted its holdings in Compass Therapeutics by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 131,789 shares of the company's stock worth $132,000 after buying an additional 12,315 shares during the period. Vanguard Group Inc. raised its holdings in Compass Therapeutics by 1.7% during the 1st quarter. Vanguard Group Inc. now owns 4,152,197 shares of the company's stock valued at $8,221,000 after acquiring an additional 71,008 shares during the period. Finally, Panagora Asset Management Inc. purchased a new stake in shares of Compass Therapeutics during the second quarter worth $68,000. 68.43% of the stock is currently owned by institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.